Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials

Background: Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular benefits. Objectives: We analyzed the impact of GLP-1RA on cardiova...

Full description

Bibliographic Details

Published in:	American Journal of Preventive Cardiology
Main Authors:	Frederick Berro Rivera, Linnaeus Louisse A. Cruz, John Vincent Magalong, Jade Monica Marie J. Ruyeras, John Paul Aparece, Nathan Ross B. Bantayan, Kyla Lara-Breitinger, Martha Gulati
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Subjects:	Glucagon-like peptide 1 receptor agonists GLP-1RA Cardiovascular outcomes Renal outcomes MACE
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666667724000473